Immune checkpoint inhibitors efficacy across solid cancers and the utility of PD-L1 as a biomarker of response: a systematic review and meta-analysis

BACKGROUND: Immune checkpoint inhibitors (ICPI) are a tumor agnostic treatment. However, trials of their use have been site specific. Here we summarize the trial data and explore the utility of programmed death-ligand 1 (PD-L1) expression as a biomarker to direct their pan-cancer use. METHOD: A syst...

Descripción completa

Detalles Bibliográficos
Autores principales: Fitzsimmons, Timothy S., Singh, Niharika, Walker, Thomas D. J., Newton, Claire, Evans, Dafydd G. R., Crosbie, Emma J., Ryan, Neil A. J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10219231/
https://www.ncbi.nlm.nih.gov/pubmed/37250628
http://dx.doi.org/10.3389/fmed.2023.1192762

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10219231/
https://www.ncbi.nlm.nih.gov/pubmed/37250628
http://dx.doi.org/10.3389/fmed.2023.1192762

Ejemplares similares